PURPOSE: To evaluate the safety and tolerability of inhaling multiple 1-L volumes of undiluted hyperpolarized xenon 129 ((129)Xe) followed by up to a 16-second breath hold and magnetic resonance (MR) imaging. MATERIALS AND METHODS: This study was approved by the institutional review board and was HIPAA compliant. Written informed consent was obtained. Forty-four subjects (19 men, 25 women; mean age, 46.1 years ± 18.8 [standard deviation]) were enrolled, consisting of 24 healthy volunteers, 10 patients with chronic obstructive pulmonary disease (COPD), and 10 age-matched control subjects. All subjects received three or four 1-L volumes of undiluted hyperpolarized (129)Xe, followed by breath-hold MR imaging. Oxygen saturation, heart rate and rhythm, and blood pressure were continuously monitored. These parameters, along with respiratory rate and subjective symptoms, were assessed after each dose. Subjects' serum biochemistry and hematology were recorded at screening and at 24-hour follow-up. A 12-lead electrocardiogram (ECG) was obtained at these times and also within 2 hours prior to and 1 hour after (129)Xe MR imaging. Xenon-related symptoms were evaluated for relationship to subject group by using a χ(2) test and to subject age by using logistic regression. Changes in vital signs were tested for significance across subject group and time by using a repeated-measures multivariate analysis of variance test. RESULTS: The 44 subjects tolerated all xenon inhalations, no subjects withdrew, and no serious adverse events occurred. No significant changes in vital signs (P > .27) were observed, and no subjects exhibited changes in laboratory test or ECG results at follow-up that were deemed clinically important or required intervention. Most subjects (91%) did experience transient xenon-related symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%). All symptoms resolved without clinical intervention in 1.6 minutes ± 0.9. CONCLUSION: Inhalation of hyperpolarized (129)Xe is well tolerated in healthy subjects and in those with mild or moderate COPD. Subjects do experience mild, transient, xenon-related symptoms, consistent with its known anesthetic properties.
PURPOSE: To evaluate the safety and tolerability of inhaling multiple 1-L volumes of undiluted hyperpolarized xenon 129 ((129)Xe) followed by up to a 16-second breath hold and magnetic resonance (MR) imaging. MATERIALS AND METHODS: This study was approved by the institutional review board and was HIPAA compliant. Written informed consent was obtained. Forty-four subjects (19 men, 25 women; mean age, 46.1 years ± 18.8 [standard deviation]) were enrolled, consisting of 24 healthy volunteers, 10 patients with chronic obstructive pulmonary disease (COPD), and 10 age-matched control subjects. All subjects received three or four 1-L volumes of undiluted hyperpolarized (129)Xe, followed by breath-hold MR imaging. Oxygen saturation, heart rate and rhythm, and blood pressure were continuously monitored. These parameters, along with respiratory rate and subjective symptoms, were assessed after each dose. Subjects' serum biochemistry and hematology were recorded at screening and at 24-hour follow-up. A 12-lead electrocardiogram (ECG) was obtained at these times and also within 2 hours prior to and 1 hour after (129)Xe MR imaging. Xenon-related symptoms were evaluated for relationship to subject group by using a χ(2) test and to subject age by using logistic regression. Changes in vital signs were tested for significance across subject group and time by using a repeated-measures multivariate analysis of variance test. RESULTS: The 44 subjects tolerated all xenon inhalations, no subjects withdrew, and no serious adverse events occurred. No significant changes in vital signs (P > .27) were observed, and no subjects exhibited changes in laboratory test or ECG results at follow-up that were deemed clinically important or required intervention. Most subjects (91%) did experience transient xenon-related symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%). All symptoms resolved without clinical intervention in 1.6 minutes ± 0.9. CONCLUSION: Inhalation of hyperpolarized (129)Xe is well tolerated in healthy subjects and in those with mild or moderate COPD. Subjects do experience mild, transient, xenon-related symptoms, consistent with its known anesthetic properties.
Authors: John P Mugler; Talissa A Altes; Iulian C Ruset; Isabel M Dregely; Jaime F Mata; G Wilson Miller; Stephen Ketel; Jeffrey Ketel; F William Hersman; Kai Ruppert Journal: Proc Natl Acad Sci U S A Date: 2010-11-22 Impact factor: 11.205
Authors: Michael Salerno; Eduard E de Lange; Talissa A Altes; Jonathon D Truwit; James R Brookeman; John P Mugler Journal: Radiology Date: 2002-01 Impact factor: 11.105
Authors: J R MacFall; H C Charles; R D Black; H Middleton; J C Swartz; B Saam; B Driehuys; C Erickson; W Happer; G D Cates; G A Johnson; C E Ravin Journal: Radiology Date: 1996-08 Impact factor: 11.105
Authors: M Ebert; T Grossmann; W Heil; W E Otten; R Surkau; M Leduc; P Bachert; M V Knopp; L R Schad; M Thelen Journal: Lancet Date: 1996-05-11 Impact factor: 79.321
Authors: Jeff Kammerman; Andrew D Hahn; Robert V Cadman; Annelise Malkus; David Mummy; Sean B Fain Journal: Magn Reson Med Date: 2020-03-11 Impact factor: 4.668
Authors: Nuwandi M Ariyasingha; Baptiste Joalland; Hassan R Younes; Oleg G Salnikov; Nikita V Chukanov; Kirill V Kovtunov; Larisa M Kovtunova; Valerii I Bukhtiyarov; Igor V Koptyug; Juri G Gelovani; Eduard Y Chekmenev Journal: Chemistry Date: 2020-09-17 Impact factor: 5.236
Authors: Laura L Walkup; Robert P Thomen; Teckla G Akinyi; Erin Watters; Kai Ruppert; John P Clancy; Jason C Woods; Zackary I Cleveland Journal: Pediatr Radiol Date: 2016-08-05
Authors: Kun Qing; John P Mugler; Talissa A Altes; Yun Jiang; Jaime F Mata; G Wilson Miller; Iulian C Ruset; F William Hersman; Kai Ruppert Journal: NMR Biomed Date: 2014-08-22 Impact factor: 4.044
Authors: Robert P Thomen; Laura L Walkup; David J Roach; Zackary I Cleveland; John P Clancy; Jason C Woods Journal: J Cyst Fibros Date: 2016-07-29 Impact factor: 5.482
Authors: Oleg G Salnikov; Kirill V Kovtunov; Panayiotis Nikolaou; Larisa M Kovtunova; Valerii I Bukhtiyarov; Igor V Koptyug; Eduard Y Chekmenev Journal: Chemphyschem Date: 2018-08-07 Impact factor: 3.102
Authors: Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys Journal: Thorax Date: 2017-08-31 Impact factor: 9.139
Authors: Zackary I Cleveland; Rohan S Virgincar; Yi Qi; Scott H Robertson; Simone Degan; Bastiaan Driehuys Journal: NMR Biomed Date: 2014-05-12 Impact factor: 4.044
Authors: Rohan S Virgincar; Zackary I Cleveland; S Sivaram Kaushik; Matthew S Freeman; John Nouls; Gary P Cofer; Santiago Martinez-Jimenez; Mu He; Monica Kraft; Jan Wolber; H Page McAdams; Bastiaan Driehuys Journal: NMR Biomed Date: 2012-10-13 Impact factor: 4.044